Dr. Mayadev on Atezolizumab Plus Chemoradiation in Locally Advanced Cervical Cancer

Video

Jyoti Mayadev, MD, discusses the phase 1 NRG-GY017 trial evaluating atezolizumab given as an immune primer or concurrently with extended field chemoradiation in patients with locally advanced, node-positive cervical cancer.

Jyoti Mayadev, MD, professor, assistant vice chair, Developmental Therapeutics, section chief, Gynecologic Oncology, co-leader, GYN Oncology Disease Team, Moores NCI-Designated Comprehensive Cancer Center, UC San Diego School of Medicine, discusses the phase 1 NRG-GY017 trial (NCT03738228) evaluating atezolizumab (Tecentriq) given as an immune primer or concurrently with extended field chemoradiation in patients with locally advanced, node-positive cervical cancer.

The key takeaway from the trial is that it was safe to combine an anti–PD-L1 agent with chemoradiation, Mayadev says. Few dose-limiting toxicities were observed with this approach in this population, Mayadev adds. Additionally, when examining T-cell clones in the patient's peripheral blood and the tumors, it was found that patients who received chemoradiation had an expansion of T-cell clonality. Notably, new, novel clones were observed, as opposed to tumor-associated clones, Mayadev concludes.

Related Videos
Hetty E. Carraway, MD, MBA, staff associate professor, Department of Medicine, School of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; member, Immune Oncology Program, Case Comprehensive Cancer Center; vice chair, Strategy and Enterprise Development, Taussig Cancer Institute, Division of Hematologic Oncology and Blood Disorders, Cleveland Clinic
David A. Braun, MD, PhD, assistant professor, medicine (medical oncology), Louis Goodman and Alfred Gilman Yale Scholar, member, Center of Molecular and Cellular Oncology, Yale Cancer Center
Julia Foldi, MD, PhD
Vikram M. Narayan, MD
C. Ola Landgren, MD, PhD
Video 14 - "Key Takeaways in HER2-Mutated NSCLC"
Video 13 - "Treatment Considerations in HER2-Mutated NSCLC"
Timothy Yap, MBBS, PhD, FRCP
Muhamed Baljevic, MD, FACP
Kathleen A. Dorritie, MD